Diffuse Large B-cell Lymphoma Therapeutics Market Trends 2029

Increasing incidence of DLBCL (Diffuse Large B-Cell Lymphoma)

Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL) that affects B-lymphocytes. Although there are more than 60 types of NHL, diffuse large B cell lymphoma (DLBCL) is the most common type, making up about 30 percent of all lymphomas

In the United States, DLBCL affects about 7 out of 100,000 people each year. DLBCL is a fast-growing, aggressive form of NHL. According to the Lymphoma Research Foundation, a U.S.-based nonprofit organization, more than 18,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed every year in the U.S. Thus, the market for diffuse large-B cell lymphoma therapeutics is expected to grow during the forecast period

As per DelveInsight's estimates, total incident cases of DLBCL in the 7MM [the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan] was observed to be 71,045 in 2020. The estimates are expected to increase due to the rising trend in the NHL incidence as well as DLBCL incidence in the 7MM, combined with underlying demographic changes in the respective markets

DLBCL most commonly affects middle-aged and older adults. The males appear to have a predisposition to DLBCL, which is why a higher percentage of incidence was observed in males as compared to females, thus driving the market growth

Increasing preference for targeted therapies

Targeted therapy is  one of the most widely preferred methods for the treatment of diffuse large B-cell lymphoma, as targeted therapy is less toxic to healthy cells than chemotherapy. Targeted therapies act on specific molecular targets that are associated with cancer

Monoclonal antibodies, kinase inhibitors, immunomodulatory drugs, and nuclear export inhibitors are among the targeted therapies used for NHL. Rituximab is a targeted therapy that is used to treat a variety of B-cell NHL types. It works by focusing on a molecule known as CD20, which is found on the surface of both normal B cells and B-cell NHL cells

Ibrutinib is a targeted therapy that inhibits the Bruton's tyrosine kinase pathway. Mantle cell lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma, as well as chronic lymphocytic leukaemia and Waldenstrom macroglobulinemia, are among the B-cell lymphomas for which it has been approved

Recent progress in molecular biology has led to a better understanding of the oncogenic drivers of DLBCL, resulting in the development of a large number of targeted therapies undergoing evaluation in phase I and II trials. Ibrutinib (Imbruvica), a targeted therapy approved by the FDA for use in multiple forms of lymphoma, has been tested in DLBCL to investigate if it affects the subtypes differently

The ABC subtype of DLBCL was found to be substantially more sensitive to ibrutinib than the GCB subtype in a recent phase II clinical trial of patients with relapsed or refractory disease.

Increasing usage of different technologie

The development of clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9) technology has shown potential to treat various cancers. CRISPR technology can be used to discover the non-coding cancer genome. 

CRISPR is a family of DNA sequence found in the genomes of prokaryotic bacteria such as archaea. CRISPR-Cas9 changes the DNA sequences and messages by inserting a cut or break in the DNA. 

The technology has entered into clinical trials in the oncology space focused on reprogramming immune cells to the target and destroys tumor cells. CRISPR-Cas9 genome editing reduces the processing associated with the generation of cell line and animal models of cancer and complex generations. It can be employed to promptly engineer oncolytic viruses and immune cells for cancer therapeutic applications. Thus, generates better cancer model for target validation and drug evaluation. 

CRISPR–Cas9 is accelerating the different stages of oncology drug discovery including target identification, validation and deconvolution, drug synthesis, assessment of drug sensitivity and resistance.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com